NDC product
Trokendi XR
NDC 17772-103 · Supernus Pharmaceuticals, Inc.
Key facts
| Product NDC | 17772-103 |
|---|---|
| Proprietary name | Trokendi XR |
| Nonproprietary name | topiramate |
| Substances | TOPIRAMATE |
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Supernus Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA201635 |
| Pharmacologic classes | Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE] |
| Marketing start | Aug 16, 2013 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: